<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-358-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SIGNIFOR 0.6 mg solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PASIREOTIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21623.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01CB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Signifor is a medicine that contains the active substance pasireotide. It is used to treat Cushing&rsquo;s disease in adult patients for whom surgery is not an option or for whom surgery has failed.</p><p>&nbsp;</p><p>Cushing&rsquo;s disease is caused by an enlargement in the pituitary gland (a gland at the base of the brain) called a pituitary adenoma. This leads the body to over‑produce a hormone called adrenocorticotropic hormone (ACTH), which in turn results in over‑production of another hormone called cortisol.</p><p>&nbsp;</p><p>The human body naturally produces a substance called somatostatin, which blocks the production of certain hormones, including ACTH. Pasireotide works in a very similar way to somatostatin. Signifor is thus able to block the production of ACTH, helping to control the over‑production of cortisol and improve the symptoms of Cushing&rsquo;s disease.</p><p>&nbsp;</p><p>If you have any questions about how Signifor works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Signifor</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to pasireotide or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor before using Signifor if you currently have or have ever had:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with your blood sugar levels, whether too high (as in diabetes) or too low (hypoglycaemia);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems such as a recent heart attack, congestive heart failure (a type of heart disease where the heart cannot pump enough blood around the body) or sudden and oppressive chest pain (usually felt as pressure, heaviness, tightening, squeezing or aching across the chest);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a heart rhythm disorder, such as an irregular heartbeat or an abnormal electrical signal called &ldquo;prolongation of the QT interval&rdquo;, or &ldquo;QT prolongation&rdquo;;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of potassium or magnesium in your blood;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gallstones.</p><p>&nbsp;</p><p>During your treatment with Signifor</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signifor controls over‑production of cortisol. The control may be too strong and you may experience signs or symptoms associated with a lack of cortisol, such as extreme weakness, tiredness, weight loss, nausea, vomiting or low blood pressure. If this happens, tell your doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signifor may cause your blood sugar to increase. Your doctor may want to monitor your blood sugar and start treatment with or adjust your antidiabetic medicine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signifor may lower your heart rate. Your doctor may wish to monitor your heart rate using a machine that measures electrical activity of the heart (an &ldquo;ECG&rdquo;, or electrocardiogram). If you are using medicine to treat a heart condition, your doctor may also need to adjust its dosage.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor may also wish to check your gallbladder, liver enzymes and pituitary hormones periodically, since these might all be affected by this medicine.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children and adolescents below 18&nbsp;years old because no data are available in this age group.</p><p>&nbsp;</p><p>Other medicines and Signifor</p><p>Signifor may affect the way some other medicines work. If you are using other medicines at the same time as Signifor (including medicines obtained without a prescription), your doctor may need to monitor your heart more carefully or change the dose of Signifor or the other medicines. Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Especially, tell your doctor if you are using:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat irregular heartbeat, such as medicines containing disopyramide, procainamide, quinidine, sotalol, dofetilide, ibutilide, amiodarone or dronedarone;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat bacterial infections (by mouth: clarithromycin, moxifloxacin; via injection: erythromycin, pentamidine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat fungal infections (ketoconazole, except in shampoo);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat certain psychiatric disorders (chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol, tiapride, amisulpride, sertindole, methadone);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat hay fever and other allergies (terfenadine, astemizole, mizolastine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used in the prevention or treatment of malaria (chloroquine, halofantrine, lumefantrine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to control blood pressure such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta blockers (metoprolol, carteolol, propranolol, sotalol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium channel blockers (bepridil, verapamil, diltiazem)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholinesterase inhibitors (rivastigmine, physostigmine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to control the balance of electrolytes (potassium, magnesium) in your body.</p><p>&nbsp;</p><p>It is particularly important that you mention any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (used in organ transplantation to reduce the activity of the immune system);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat blood sugar levels that are too high (as in diabetes) or too low (hypoglycaemia), such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insulin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin, liraglutide, vildagliptin, nateglinide (antidiabetic medicines).</p><p>&nbsp;</p><p>Pregnancy, breast‑feeding and fertility</p><p>Ask your doctor or pharmacist for advice before using any medicine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not use Signifor during pregnancy unless clearly necessary. If you are pregnant or think that you may be, it is important to tell your doctor who will discuss with you whether you can use Signifor during your pregnancy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not breast‑feed while using Signifor. It is not known whether Signifor passes into breast milk.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a sexually active woman, you should use an effective method of contraception during treatment. Ask your doctor about the need for contraception before taking this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Signifor may have a minor effect on the ability to drive and use machines, because some of the side effects you may experience while using Signifor, such as headache and tiredness, may reduce your ability to drive and use machines safely.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of Signifor</strong></p><p>Signifor contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, which means it is essentially &ldquo;sodium‑free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. This medicine comes in an ampoule, i.e. a small glass container.</p><p>&nbsp;</p><p>How much Signifor to use</p><p>The recommended dose is one ampoule of Signifor 0.6&nbsp;mg twice a day. Using Signifor at the same time each day will help you remember when to use your medicine. After you have started treatment, your doctor may also decide to increase your dose to one ampoule of Signifor 0.9&nbsp;mg twice a day.</p><p>&nbsp;</p><p>If side effects occur your doctor may temporarily reduce your dose by 0.3&nbsp;mg per injection.</p><p>&nbsp;</p><p>If you have liver disease before you start Signifor treatment, your doctor may want to start your treatment with a dose of one ampoule of Signifor 0.3&nbsp;mg twice a day.</p><p>&nbsp;</p><p>Ampoules of Signifor of different strengths (0.3&nbsp;mg, 0.6&nbsp;mg and 0.9&nbsp;mg) are available to match the specific dose prescribed by your doctor.</p><p>&nbsp;</p><p>Your doctor will check regularly how you respond to the treatment with Signifor and determine which dose is best for you.</p><p>&nbsp;</p><p>How to use Signifor</p><p>Your doctor or nurse will instruct you on how to inject yourself with Signifor. You should also read the instructions at the end of this leaflet. If you have any questions, contact your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>Signifor is intended for subcutaneous use. This means that it is injected through a short needle into the fatty tissue just under the skin. The thighs and the abdomen are good areas for subcutaneous injection. Avoid soreness and skin irritation by choosing a different site from the previous one for each injection. You should also avoid injections at sites that are sore or where the skin is irritated.</p><p>&nbsp;</p><p>Do not use Signifor if you notice the solution is not clear or contains particles. The solution should be free of visible particles, clear and colourless.</p><p>&nbsp;</p><p>How long to use Signifor</p><p>You should continue using Signifor for as long as your doctor tells you to.</p><p><u>&nbsp;</u></p><p>If you use more Signifor than you should</p><p>If you accidentally use more Signifor than your doctor prescribed, immediately contact your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>If you forget to use Signifor</p><p>Do not inject a double dose of Signifor to make up for a forgotten dose. If you forgot to inject a dose of Signifor, simply inject the next dose at the scheduled time.</p><p>&nbsp;</p><p>If you stop using Signifor</p><p>If you interrupt your treatment with Signifor your cortisol level may increase again and your symptoms may come back. Therefore, do not stop using Signifor unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects may be serious. Tell your doctor straight away if you get any of the following:</strong></p><p>&nbsp;</p><p>Very common (may affect more than 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changed level of sugar in the blood. You may experience excessive thirst, high urine output, increased appetite with weight loss, tiredness.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones. You may experience sudden back pain or pain in the right side of your abdomen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extreme tiredness.</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low cortisol levels. You may experience extreme weakness, tiredness, weight loss, nausea, vomiting and low blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart beat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure. You may experience dizziness, light headedness and dizziness or fainting on standing up.</p><p>&nbsp;</p><p><strong>Other side effects of Signifor may include:</strong></p><p>&nbsp;</p><p>Very common (may affect more than 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain at the injection site</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged QT interval (an abnormal electrical signal in your heart that can be seen in tests)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching (pruritus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain (myalgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain (arthralgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal results of liver function tests</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal results of pancreatic function tests</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal blood coagulation properties</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of red blood cells (anaemia)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 25⁰C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the ampoule label and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance<strong> </strong>is pasireotide.</p><p>Signifor 0.3&nbsp;mg: One ampoule of 1&nbsp;ml solution contains 0.3&nbsp;mg pasireotide (as pasireotide diaspartate).</p><p>Signifor 0.6&nbsp;mg: One ampoule of 1&nbsp;ml solution contains 0.6&nbsp;mg pasireotide (as pasireotide diaspartate).</p><p>Signifor 0.9&nbsp;mg: One ampoule of 1&nbsp;ml solution contains 0.9&nbsp;mg pasireotide (as pasireotide diaspartate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol, tartaric acid, sodium hydroxide and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Signifor solution for injection is a clear, colourless solution in an ampoule. Each ampoule contains 1 ml of solution for injection.
	
	Signifor is available in packs containing 6 ampoules or in multipacks containing 60 (10 packs of 6) ampoules.
	
	Not all strengths or pack sizes may be marketed in your country.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com<u> &nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Feb 2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سيغنيفور على المادة الفعالة باسيريوتايد. وهو يستخدم لعلاج مرض كوشينغ لدى المرضى البالغين الذين لا يمكن خضوعهم للجراحة أو الذين قد فشلت العملية الجراحية التي أُجريت لهم.</p><p dir="RTL">تتم الإصابة بمرض كوشينغ نتيجة لتضخم الغدة النخامية (غدة توجد في قاعدة المخ) يسمى بالورم الغدي النخامي. يؤدي ذلك إلى قيام الجسم بالإنتاج المفرط لهرمون يسمى الهرمون الموجه للقشرة الكظرية (ACTH)، وهو ما يؤدي بدوره لفرط إنتاج هرمون آخر يسمى الكورتيزول.</p><p dir="RTL">ينتج الجسم البشري بصورة طبيعية مادة تسمى سوماتوستاتين، والتي تحصر إنتاج هرمونات بعينها، ومنها الهرمون الموجه للقشرة الكظرية. يعمل باسيريوتايد بطريقة شبيهة للغاية بسوماتوستاتين. لذلك، يستطيع سيغنيفور حصر إنتاج الهرمون الموجه للقشرة الكظرية، مما يساعد في ضبط الإنتاج المفرط للكورتيزول ويحسن أعراض مرض كوشينغ.</p><p dir="RTL">إن كانت لديك أسئلة بخصوص كيفية عمل سيغنيفور أو سبب وصف هذا الدواء لك، فاستشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام </strong><strong>سيغنيفور</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بالحساسية تجاه باسيريوتايد أو أي من المكونات الأخرى في هذا الدواء (مسرود في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بمشكلات كبدية شديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">استشر طبيبك قبل استخدام سيغنيفور إن كنت مصابًا حاليًا أو سبقت إصابتك بأي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات تخص مستويات السكر في دمك، سواءً كانت بالغة الارتفاع (كالسكري) أو بالغة الانخفاض (نقص الجلوكوز في الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات القلب، كالإحصار القلبي الحديث، أو الفشل القلبي الاحتقاني (نوع من أمراض القلب لا يكون بإمكان القلب فيه ضخ ما يكفي من الدم للجسم) أو ألم الصدر المفاجئ ثقيل الوطأة (عادةً ما يشبه شعورًا بالضغط، أو الثقل، أو الضيق، أو العصر أو الوجع في الصدر)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نظم القلب، كعدم انتظام ضربات القلب أو إشارة كهربية شاذة تسمى &quot;تطاول الفاصل كيو تي&quot; أو &quot;تطاول كيو تي&quot;؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم أو الماغنسيوم في دمك؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصوات المرارة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>خلال العلاج باستخدام سيغنيفور</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يسيطر سيغنيفور على فرط إنتاج الكورتيزول. قد تكون تلك السيطرة بالغة القوة، وقد تصاب بعلامات أو أعراض تصاحب نقص الكورتيزول، كالضعف البالغ، أو الإرهاق، أو نقص الوزن، أو الغثيان، أو القيء أو انخفاض ضغط الدم. إن حدث ذلك، فأبلغ طبيبك فورًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب سيغنيفور زيادة سكر الدم. قد يرغب طبيبك في إجراء مراقبة لمستوى السكر في دمك وبدء العلاج بدواء مضاد للسكري أو تعديل دوائك المضاد للسكري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يخفض سيغنيفور معدل نبض القلب. قد يرغب طبيبك في إجراء مراقبة لمعدل نبض قلبك باستخدام آلة تقيس النشاط الكهربي للقلب (تسمى اختصارًا &quot;ECG&quot;، أو رسم القلب الكهربي). إن كنت تستخدم دواءً لعلاج حالة قلبية، فقد يحتاج طبيبك كذلك لتعديل جرعاته.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يرغب طبيبك في فحص مرارتك، وإنزيماتك الكبدية والهرمونات النخامية دوريًا، حيث قد يتأثر ذلك كله نتيجةً لهذا الدواء. &nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطِ هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا لعدم توفر بيانات بخصوص تلك الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسيغنيفور</strong></p><p dir="RTL">قد يؤثر سيغنيفور على الآلية التي تعمل بها بعض الأدوية. إن كنت تستخدم أدوية أخرى في نفس الوقت مع سيغنيفور (بما في ذلك الأدوية التي يمكن الحصول عليها دون وصفة طبية)، فقد يحتاج طبيبك إلى مراقبة قلبك بدقة أكثر أو إلى تغيير جرعة سيغنيفور أو الأدوية الأخرى. أبلغ طبيبك أو الصيدلي إن كنت تستخدم أي أدوية أخرى حاليًا أو مؤخرًا. أبلغ طبيبك بصفة خاصة إن كنت تستخدم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج اضطراب نبض القلب، كالأدوية التي تحتوي ديسوبيراميد، بروكيناميد، كينيدين، سوتالول، دوفيتيليد، أميودارون أو درونيدارون،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج العدوى البكتيرية (فمويًا: كلاريثرومايسين، وموكسيفلوكزاسين، أو عن طريق الحقن: إريثرومايسين، وبنتاميدين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج العدوى الفطرية (كيتوكونازول، باستثناء الشامبو)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج اضطرابات نفسية معينة (كلوربرومازين، ثيوريدازين، فلوفينازين، بيموزايد، هالوبيريدول، تيابرايد، آميسالبرايد، سيرتيندول، ميثادون)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج حمى القش والحساسيات الأخرى (تيرفينادين، أستيميزول، ميزولاستين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة للوقاية من الملاريا وعلاجها (كلوروكين، هالوفانترين، لوميفانترين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية ضبط ضغط الدم مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات البيتا (ميتوبرولول، كارتيولول، بروبرانولول، سوتالول)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات قناة الكالسيوم (بيبريديل، فيراباميل، ديلتيازيم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الكولين إستريز (ريفاستيغمين، فايزوستيغمين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية ضبط اتزان الإلكتروليتات (البوتاسيوم، والماغنسيوم) في جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم بصفة خاصة أن تذكر أيًا من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (يستخدم في زراعة الأعضاء للحد من نشاط الجهاز المناعي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج مستويات سكر الدم بالغة الارتفاع (كما هو الحال في السكري) أو بالغة الانخفاض (نقص جلوكوز الدم) مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنسولين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتفورمين، ليراغلوتيد، فيلداغليبتين، ناتيغلينايد (أدوية مضادة للسكري).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">استشيري طبيبكِ أو الصيدلي قبل استخدام أي أدوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب أن تستخدمي سيغنيفور خلال الحمل ما لم يكن ذلك ضروريًا بوضوح. إن كنتِ حاملًا أو تشكين في حملكِ، فمن المهم أن تبلغي طبيبكِ الذي سيناقشكِ بخصوص إمكانية استخدامك سيغنيفور خلال حملكِ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب أن تُرضعي خلال استخدام سيغنيفور. ليس من المعروف ما إذا كان سيغنيفور يُمتص في لبن الأم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنتِ سيدة نشطة جنسيًا، فعليكِ استخدام طريقة فعالة لمنع الحمل خلال العلاج. اسألي طبيبكِ بخصوص الحاجة لمنع الحمل قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات وتشغيل الآلات</strong></p><p dir="RTL">قد يكون لسيغنيفور أثر ضئيل في القدرة على قيادة المركبات وتشغيل الآلات، نظرًا لأن بعض الآثار الجانبية التي قد تصاب بها خلال استخدام سيغنيفور، كالصداع والتعب، قد تحد من قدرتك على قيادة المركبات وتشغيل الآلات بأمان.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة بخصوص بعض مكونات سيغنيفور</strong></p><p dir="RTL">يحتوي سيغنيفور على أقل من 1 مللي مول من الصوديوم (23 ملجم) في كل جرعة، وهو ما يعني أنه أساسًا &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دائمًا بالطريقة التي أبلغك بها طبيبك. راجع طبيبك أو الصيدلي إن كنت في شك من طريقة استخدامه. يتوفر هذا الدواء في أمبولة، أي حاوية زجاجية صغيرة.</p><p dir="RTL"><strong>الكمية التي يجب استخدامها من سيغنيفور</strong></p><p dir="RTL">الجرعة الموصى بها هي أمبولة واحدة من سيغنيفور 0.6 ملجم مرتين يوميًا. سيساعدك استخدام سيغنيفور في نفس الوقت من كل يوم في أن تتذكر موعد استخدامك للدواء. كما قد يقرر طبيبك أيضًا بعد بدء العلاج زيادة جرعتك إلى أمبولة واحدة من سيغنيفور 0.9 ملجم مرتين يوميًا.</p><p dir="RTL">إفي حالة حدوث آثار جانبية، قد يقلل طبيبك جرعتك بمقدار 0.3 ملجم لكل حقنة.</p><p dir="RTL">إن كنت مصابًا بمرض كبدي قبل بدء العلاج باستخدام سيغنيفور، فقد يرغب طبيبك في أن يبدأ علاجك بجرعة أمبولة واحدة من سيغنيفور 0.3 ملجم مرتين يوميًا.</p><p dir="RTL">تتوفر أمبولات سيغنيفور بتركيزات مختلفة (0.3 ملجم، و0.6 ملجم و0.9 ملجم) لتفي بالجرعة المحددة التي يصفها طبيبك.</p><p dir="RTL">سيفحص طبيبك بانتظام كيفية استجابتك للعلاج باستخدام سيغنيفور وسيحدد الجرعة الأنسب لك.</p><p dir="RTL"><strong>كيفية استخدام سيغنيفور</strong></p><p dir="RTL">سيرشدك طبيبك أو ممرضتك إلى كيفية حقن نفسك بسيغنيفور. عليك كذلك قراءة التعليمات الموجودة في نهاية هذه النشرة. إن كانت لديك اسئلة، فاتصل بطبيبك، أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيغنيفور مخصص للاستخدام تحت الجلد. يعني ذلك أنه يُحقن باستخدام إبرة قصيرة في النسيج الشحمي الذي يوجد أسفل الجلد مباشرة. الفخذين والبطن تعد مناطق مناسبة للحقن تحت الجلد. تفادى تقرح وتهيج الجلد عن طريق اختيار موضع مختلف للحقن في كل مرة. عليك كذلك تفادي الحقن في الأماكن المتقرحة أو مناطق تهيج الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم سيغنيفور إن لاحظت عدم صفاء المحلول أو احتوائه جسيمات. يفترض أن يكون المحلول خاليًا من الجسيمات الظاهرة، وصافيًا، وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كم مدة استخدام سيغنيفور</strong></p><p dir="RTL">عليك أن تستمر في استخدام سيغنيفور للمدة التي يحددها لك طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إن أفرطت في الكمية المستخدمة من سيغنيفور</strong></p><p dir="RTL">إن استخدمت عن طريق الخطأ كمية من سيغنيفور تفوق تلك التي وصفها طبيبك، فاتصل فورًا بطبيبك، أو الممرضة أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إن نسيت استخدام سيغنيفور</strong></p><p dir="RTL">لا تحقن جرعة مزدوجة من سيغنيفور لتعويض جرعة منسية. إن نسيت حقن جرعة من سيغنيفور، فاحقن الجرعة التالية ببساطة في موعدها المقرر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إن أوقفت استخدام سيغنيفور</strong></p><p dir="RTL">إن انقطعت عن علاجك باستخدام سيغنيفور فقد يرتفع مستوى الكورتيزول لديك مرة أخرى وقد تعود أعراضك. لذلك، لا توقف استخدام سيغنيفور ما لم يبلغك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كان لديك المزيد من الأسئلة بخصوص استخدام هذا الدواء، فاستشر طبيبك، أو الممرضة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن لهذا الدواء -ككل الأدوية- أن يسبب آثارًا جانبية، رغم أنها لا تصيب الجميع.</p><p dir="RTL"><strong>قد تكون بعض الآثار الجانبية خطيرة. أبلغ طبيبك فورًا إن أصبت بأي مما يلي:</strong></p><p dir="RTL">بالغة الشيوع (قد تصيب أكثر من 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير مستوى السكر في الدم. قد تصاب بالعطش المفرط، أو ارتفاع الناتج البولي، أو فرط الشهية مع نقص الوزن، أو الإرهاق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصوات المرارة. قد تصاب بألم مفاجئ في الظهر أو بألم في الجانب الأيمن من بطنك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق البالغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة (قد تصيب حتى 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الكورتيزول. قد تصاب بالضعف البالغ، والإرهاق، ونقص الوزن، والغثيان، والقيء وانخفاض ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ نبض القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم. قد تصاب بالدوخة، وخفة الرأس والدوخة أو الإغماء عند النهوض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تتضمن باقي الآثار الجانبية لسيغنيفور ما يلي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بالغة الشيوع (قد تصيب أكثر من 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بموضع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة (قد تصيب حتى 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تطاول الفاصل كيو تي (إشارة كهربية شاذة في قلبك يمكن ملاحظتها في الاختبارات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرش (الحكة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات (وجع العضلات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل (وجع المفاصل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج شاذة لاختبارات الوظيفة الكبدية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج شاذة لاختبارات وظيفة البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خصائص شاذة لتجلط الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (قد تصيب حتى 1 من كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى كريات الدم الحمراء (فقر الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن أصبت بأي آثار جانبية، فأبلغ طبيبك، أو الممرضة أو الصيدلي. يتضمن ذلك أي آثار جانبية ممكنة غير مفصلة في هذه النشرة. ستساعد بإبلاغك عن الآثار الجانبية في توفير المزيد من المعلومات بخصوص أمان هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يخزن فوق 25 ⁰م.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بهذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على وسم الأمبولة وعلى العلبة الكارتونية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية لليوم الأخير من ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخزن في عبوته الأصلية لحمايته من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية من خلال مياه الصرف الصحي أو الفضلات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي كففت عن استخدامها. ستساعد تلك الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي باسيريوتايد.</p><p dir="RTL">سيغنيفور 0.3 ملجم: تحتوي الأمبولة الواحدة على 1 مللي من محلول يحتوي 0.3 ملجم من باسيريوتايد (في صورة باسيريوتايد ثنائي الأسبرتيت).</p><p dir="RTL">سيغنيفور 0.6 ملجم: تحتوي الأمبولة الواحدة على 1 مللي من محلول يحتوي 0.6 ملجم من باسيريوتايد (في صورة باسيريوتايد ثنائي الأسبرتيت).</p><p dir="RTL">سيغنيفور 0.3 ملجم: تحتوي الأمبولة الواحدة على 9 مللي من محلول يحتوي 0.9 ملجم من باسيريوتايد (في صورة باسيريوتايد ثنائي الأسبرتيت).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضم باقي المكونات المانيتول، وحمض الطرطريك، وهيدروكسيد الصوديوم وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">محلول سيغنيفور للحقن هو محلول صافٍ، عديم اللون في أمبولة. تحتوي كل أمبولة على 1 مللي من المحلول للحقن.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">يتوفر سيغنيفور في عبوات تحتوي 6 أمبولات أو في عبوات متعددة تحتوي 60 (10 عبوات من 6 أمبولات).</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">لا يُشترط أن تتوفر جميع التركيزات أو جميع أحجام العبوات في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Signifor 0.3 mg solution for injection
Signifor 0.6 mg solution for injection
Signifor 0.9 mg solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Signifor 0.3 mg solution for injection
One ampoule of 1 ml contains 0.3 mg pasireotide (as pasireotide diaspartate).

Signifor 0.6 mg solution for injection
One ampoule of 1 ml contains 0.6 mg pasireotide (as pasireotide diaspartate).

Signifor 0.9 mg solution for injection
One ampoule of 1 ml contains 0.9 mg pasireotide (as pasireotide diaspartate).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signifor is indicated for the treatment of adult patients with Cushing&rsquo;s disease for whom surgery is not an option or for whom surgery has failed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The recommended initial dose is 0.6&nbsp;mg pasireotide by subcutaneous injection twice a day.</p><p>&nbsp;</p><p>Two months after the start of Signifor therapy, patients should be evaluated for clinical benefit. Patients who experience a significant reduction in urinary free cortisol (UFC) levels should continue to receive Signifor for as long as benefit is derived. A dose increase to 0.9&nbsp;mg may be considered based on the response to the treatment, as long as the 0.6&nbsp;mg dose is well tolerated by the patient. Patients who have not responded to Signifor after two months of treatment should be considered for discontinuation.</p><p>&nbsp;</p><p>Management of suspected adverse reactions at any time during the treatment may require temporary dose reduction of Signifor. Dose reduction by decrements of 0.3&nbsp;mg twice a day is suggested.</p><p>&nbsp;</p><p>If a dose of Signifor is missed, the next injection should be administered at the scheduled time. Doses should not be doubled to make up for a missed dose.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Signifor in children and adolescents aged 0 to 18&nbsp;years have not been established. No data are available.</p><p>&nbsp;</p><p><em>Elderly patients (&ge;65&nbsp;years)</em></p><p>Data on the use of Signifor in patients older than 65&nbsp;years are limited, but there is no evidence to suggest that dose adjustment is required in these patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with impaired renal function (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Dose adjustment is not required in patients with mildly impaired hepatic function (Child Pugh A). The recommended initial dose for patients with moderate hepatic impairment (Child Pugh B) is 0.3&nbsp;mg twice a day (see section&nbsp;5.2). The maximum recommended dose for these patients is 0.6&nbsp;mg twice a day. Signifor should not be used in patients with severe hepatic impairment (Child Pugh C) (see sections&nbsp;4.3 and 4.4).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Signifor is to be administered subcutaneously by self injection. Patients should receive instructions from the physician or a healthcare professional on how to inject Signifor subcutaneously.</p><p>&nbsp;</p><p>Use of the same injection site for two consecutive injections is not recommended. Sites showing signs of inflammation or irritation should be avoided. Preferred injection sites for subcutaneous injections are the top of the thighs and the abdomen (excluding the navel or waistline).</p><p>&nbsp;</p><p>For further details on handling, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Severe hepatic impairment (Child Pugh C).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Glucose metabolism</u></p><p>&nbsp;</p><p>Alterations in blood glucose levels have been frequently reported in healthy volunteers and patients treated with pasireotide. Hyperglycaemia and, less frequently, hypoglycaemia, were observed in subjects participating in clinical studies with pasireotide (see section&nbsp;4.8).</p><p>&nbsp;</p><p>The degree of hyperglycaemia appeared to be higher in patients with pre‑diabetic conditions or established diabetes mellitus. During the pivotal study, HbA<sub>1c</sub> levels increased significantly and stabilised but did not return to baseline values (see section&nbsp;4.8). More cases of discontinuation and a higher reporting rate of severe adverse events due to hyperglycaemia were reported in patients treated with the dose of 0.9&nbsp;mg twice daily.</p><p>&nbsp;</p><p>The development of hyperglycaemia appears to be related to decreases in secretion of insulin (particularly in the post‑dose period) and of incretin hormones (i.e. glucagon‑like peptide-1 [GLP-1] and glucose‑dependent insulinotropic polypeptide [GIP]).</p><p>&nbsp;</p><p>Glycaemic status (fasting plasma glucose/haemoglobin A<sub>1c</sub> [FPG/HbA<sub>1c</sub>]) should be assessed prior to starting treatment with pasireotide. FPG/HbA<sub>1c</sub> monitoring during treatment should follow established guidelines. Self monitoring of blood glucose and/or FPG assessments should be done weekly for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase. In addition, monitoring of FPG 4&nbsp;weeks and HbA<sub>1c</sub> 3&nbsp;months after the end of the treatment should be performed.</p><p>&nbsp;</p><p>If hyperglycaemia develops in a patient being treated with Signifor, the initiation or adjustment of antidiabetic treatment is recommended, following the established treatment guidelines for the management of hyperglycaemia. If uncontrolled hyperglycaemia persists despite appropriate medical management, the dose of Signifor should be reduced or Signifor treatment discontinued (see also section&nbsp;4.5).</p><p>&nbsp;</p><p>Cushing&rsquo;s disease patients with poor glycaemic control (as defined by HbA<sub>1c</sub> values &gt;8% while receiving antidiabetic therapy) may be at higher risk of developing severe hyperglycaemia and associated complications (e.g. ketoacidosis). In patients with poor glycaemic control, diabetes management and monitoring should be intensified prior to initiation and during pasireotide therapy.</p><p>&nbsp;</p><p><u>Liver tests</u></p><p>&nbsp;</p><p>Mild transient elevations in aminotransferases are commonly observed in patients treated with pasireotide. Rare cases of concurrent elevations in ALT (alanine aminotransferase)<strong> </strong>greater than 3&nbsp;x&nbsp;ULN and bilirubin greater than 2&nbsp;x&nbsp;ULN have also been observed (see section&nbsp;4.8). Monitoring of liver function is recommended prior to treatment with pasireotide and after one, two, four, eight and twelve weeks during treatment. Thereafter liver function should be monitored as clinically indicated.</p><p>&nbsp;</p><p>Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding. If the finding is confirmed, the patient should be followed with frequent liver function monitoring until values return to pre‑treatment levels. Therapy with pasireotide should be discontinued if the patient develops jaundice or other signs suggestive of clinically significant liver dysfunction, in the event of a sustained increase in AST (aspartate aminotransferase) or ALT of 5&nbsp;x&nbsp;ULN or greater, or if ALT or AST elevations greater than 3&nbsp;x&nbsp;ULN occur concurrently with bilirubin elevations greater than 2&nbsp;x&nbsp;ULN. Following discontinuation of treatment with pasireotide, patients should be monitored until resolution. Treatment should not be restarted.</p><p>&nbsp;</p><p><u>Cardiovascular related events</u></p><p>&nbsp;</p><p>Bradycardia has been reported with the use of pasireotide (see section&nbsp;4.8). Careful monitoring is recommended in patients with cardiac disease and/or risk factors for bradycardia, such as history of clinically significant bradycardia or acute myocardial infarction, high‑grade heart block, congestive heart failure (NYHA Class&nbsp;III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation. Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or medicinal products to control electrolyte balance, may be necessary (see also section&nbsp;4.5).</p><p>&nbsp;</p><p>Pasireotide has been shown to prolong the QT interval on the ECG in two dedicated healthy volunteer studies. The clinical significance of this prolongation is unknown.</p><p>&nbsp;</p><p>In clinical studies in Cushing&rsquo;s disease patients, QTcF of &gt;500&nbsp;msec was observed in two out of 201&nbsp;patients. These episodes were sporadic and of single occurrence with no clinical consequence observed. Episodes of torsade de pointes were not observed either in those studies or in clinical studies in other patient populations.</p><p>&nbsp;</p><p>Pasireotide should be used with caution and the benefit risk carefully weighed in patients who are at significant risk of developing prolongation of QT, such as those:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with congenital long QT syndrome.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taking antiarrhythmic medicinal products or other substances that are known to lead to QT prolongation (see section&nbsp;4.5).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with hypokalaemia and/or hypomagnesaemia.</p><p>&nbsp;</p><p>Monitoring for an effect on the QTc interval is advisable and ECG should be performed prior to the start of Signifor therapy, one week after the beginning of the treatment and as clinically indicated thereafter. Hypokalaemia and/or hypomagnesaemia must be corrected prior to administration of Signifor and should be monitored periodically during therapy.</p><p>&nbsp;</p><p><u>Hypocortisolism</u></p><p>&nbsp;</p><p>Treatment with Signifor leads to rapid suppression of ACTH (adrenocorticotropic hormone) secretion in Cushing&rsquo;s disease patients. Rapid, complete or near‑complete suppression of ACTH may lead to a decrease in circulating levels of cortisol and potentially to transient hypocortisolism/hypoadrenalism.</p><p>&nbsp;</p><p>It is therefore necessary to monitor and instruct patients on the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyperkalaemia, hyponatraemia, hypoglycaemia). In the event of documented hypocortisolism, temporary exogenous steroid (glucocorticoid) replacement therapy and/or dose reduction or interruption of Signifor therapy may be necessary.</p><p>&nbsp;</p><p><u>Gallbladder and related events</u></p><p>&nbsp;</p><p>Cholelithiasis is a recognised adverse reaction associated with long‑term use of somatostatin analogues and has frequently been reported in clinical studies with pasireotide (see section&nbsp;4.8). Ultrasonic examination of the gallbladder before and at 6 to 12&nbsp;month intervals during Signifor therapy is therefore recommended. The presence of gallstones in Signifor‑treated patients is largely asymptomatic; symptomatic stones should be managed according to clinical practice.</p><p>&nbsp;</p><p><u>Pituitary hormones</u></p><p>&nbsp;</p><p>As the pharmacological activity of pasireotide mimics that of somatostatin, inhibition of pituitary hormones other than ACTH cannot be ruled out. Monitoring of pituitary function (e.g. TSH/free T<sub>4</sub>, GH/IGF-1) before and periodically during Signifor therapy should therefore be considered, as clinically appropriate.</p><p>&nbsp;</p><p><u>Effect on female fertility</u></p><p>&nbsp;</p><p>The therapeutic benefits of a reduction or normalisation of serum cortisol levels in female patients with Cushing&rsquo;s disease could potentially restore fertility. Female patients of childbearing potential should be advised to use adequate contraception during treatment with Signifor (see section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>Due to the increase in unbound drug exposure, Signifor should be used with caution in patients with severe renal impairment or end stage renal disease (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol (23&nbsp;mg) sodium per dose, i.e. it is essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Anticipated pharmacokinetic interactions resulting in effects on pasireotide</u></p><p><em>&nbsp;</em></p><p>The influence of the P‑gp inhibitor verapamil on the pharmacokinetics of subcutaneous pasireotide was tested in a drug‑drug interaction study in healthy volunteers. No change in the pharmacokinetics (rate or extent of exposure) of pasireotide was observed.</p><p>&nbsp;</p><p><u>Anticipated pharmacokinetic interactions resulting in effects on other medicinal products</u></p><p>&nbsp;</p><p>Pasireotide may decrease the relative bioavailability of ciclosporin. Concomitant administration of pasireotide and ciclosporin may require adjustment of the ciclosporin dose to maintain therapeutic levels.</p><p>&nbsp;</p><p><u>Anticipated pharmacodynamic interactions</u></p><p>&nbsp;</p><p><em>Medicinal products that prolong the QT interval</em></p><p>Pasireotide should be used with caution in patients who are concomitantly receiving medicinal products that prolong the QT interval, such as class Ia antiarrhythmics (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmics (e.g. amiodarone, dronedarone, sotalol, dofetilide, ibutilide), certain antibacterials (intravenous erythromycin, pentamidine injection, clarithromycin, moxifloxacin), certain antipsychotics (e.g. chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol, tiapride, amisulpride, sertindole, methadone), certain antihistamines (e.g. terfenadine, astemizole, mizolastine), antimalarials (e.g. chloroquine, halofantrine, lumefantrine), certain antifungals (ketoconazole, except in shampoo) (see also section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Bradycardic medicinal products</em></p><p>Clinical monitoring of heart rate, notably at the beginning of treatment, is recommended in patients receiving pasireotide concomitantly with bradycardic medicinal products, such as beta blockers (e.g. metoprolol, carteolol, propranolol, sotalol), acetylcholinesterase inhibitors (e.g. rivastigmine, physostigmine), certain calcium channel blockers (e.g. verapamil, diltiazem, bepridil), certain antiarrhythmics (see also section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Insulin and antidiabetic medicinal products</em></p><p>Dose adjustments (decrease or increase) of insulin and antidiabetic medicinal products (e.g. metformin, liraglutide, vildagliptin, nateglinide) may be required when administered concomitantly with pasireotide (see also section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There is a limited amount of data from the use of pasireotide in pregnant women. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3). Pasireotide is not recommended for use during pregnancy and in women of childbearing potential who are not using contraception (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Breast</u><u>‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether pasireotide is excreted in human milk. Available data in rats have shown excretion of pasireotide in milk (see section&nbsp;5.3). Breast‑feeding should be discontinued during treatment with Signifor.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Studies in rats have shown effects on female reproductive parameters (see section&nbsp;5.3). The clinical relevance of these effects in humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signifor may have a minor influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines if they experience fatigue or headache during treatment with Signifor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>A total of 201&nbsp;Cushing&rsquo;s disease patients received Signifor in phase&nbsp;II and III studies. The safety profile of Signifor was consistent with the somatostatin analogue class, except for the occurrence of hypocortisolism and degree of hyperglycaemia.</p><p>&nbsp;</p><p>The data described below reflect exposure of 162&nbsp;Cushing&rsquo;s disease patients to Signifor in the phase&nbsp;III study. At study entry patients were randomised to receive twice‑daily doses of either 0.6&nbsp;mg or 0.9&nbsp;mg Signifor. The mean age of patients was approximately 40&nbsp;years and the majority of patients (77.8%) were female. Most (83.3%) patients had persistent or recurrent Cushing&rsquo;s disease and few (&le;5%) in either treatment group had received previous pituitary irradiation. The median exposure to the treatment up to the cut‑off date of the primary efficacy and safety analysis was 10.37&nbsp;months (0.03‑37.8), with 66.0% of patients having at least six&nbsp;months&rsquo; exposure.</p><p>&nbsp;</p><p>Grade&nbsp;1 and 2 adverse reactions were reported in 57.4% of patients. Grade&nbsp;3 adverse reactions were observed in 35.8% of patients and Grade&nbsp;4 adverse reactions in 2.5% of patients. Grade&nbsp;3 and 4 adverse reactions were mostly related to hyperglycaemia. The most common adverse reactions (incidence &ge;10%) were diarrhoea, nausea, abdominal pain, cholelithiasis, injection site reactions, hyperglycaemia, diabetes mellitus, fatigue and glycosylated haemoglobin increased.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions reported up to the cut‑off date of the analysis are presented in Table&nbsp;1. Adverse reactions are listed according to MedDRA primary system organ class. Within each system organ class, adverse reactions are ranked by frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. Frequencies were defined as follows: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100).</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions in the phase&nbsp;III study in Cushing&rsquo;s disease patients</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Adrenal insufficiency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Hyperglycaemia, diabetes mellitus</p></td><td style="vertical-align:top"><p>Decreased appetite, type 2 diabetes mellitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sinus bradycardia, QT prolongation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea, abdominal pain, nausea</p></td><td style="vertical-align:top"><p>Vomiting, abdominal pain upper</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Cholelithiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia, pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia, arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Injection site reaction, fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Glycosylated haemoglobin increased</p></td><td style="vertical-align:top"><p>Gamma glutamyltransferase increased, alanine aminotransferase increased, lipase increased, blood glucose increased, blood amylase increased, prothrombin time prolonged</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Glucose metabolism disorders</em></p><p>Elevated glucose was the most frequently reported Grade&nbsp;3 laboratory abnormality (23.2% of patients) in the phase&nbsp;III study in Cushing&rsquo;s disease patients. Mean HbA<sub>1c</sub> increases were less pronounced in patients with normal glycaemia (n=62 overall) at study entry (i.e. 5.29% and 5.22% at baseline and 6.50% and 6.75% at month&nbsp;6 for the 0.6 and 0.9&nbsp;mg twice daily dose groups, respectively) relative to pre‑diabetic patients (i.e. n=38 overall; 5.77% and 5.71% at baseline and 7.45% and 7.13% at month&nbsp;6) or diabetic patients (i.e. n=54 overall; 6.50% and 6.42% at baseline and 7.95% and 8.30% at month&nbsp;6). Mean fasting plasma glucose levels commonly increased within the first month of treatment, with decreases and stabilisation observed in subsequent months. Fasting plasma glucose and HbA<sub>1c</sub> values generally decreased over the 28&nbsp;days following pasireotide discontinuation but remained above baseline values. Long‑term follow‑up data are not available. Patients with baseline HbA<sub>1c</sub> &ge;7% or who were taking antidiabetic medicinal products prior to randomisation tended to have higher mean changes in fasting plasma glucose and HbA<sub>1c</sub> relative to other patients. Adverse reactions of hyperglycaemia and diabetes mellitus led to study discontinuation in 5 (3.1%) and 4 (2.5%) patients, respectively. One case of ketosis and one case of ketoacidosis have been reported during compassionate use of Signifor.</p><p>&nbsp;</p><p>Monitoring of blood glucose levels in patients treated with Signifor is recommended (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>Gastrointestinal disorders were frequently reported with Signifor. These reactions were usually of low grade, required no intervention and improved with continued treatment.</p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>Injection site reactions were reported in 13.6% of patients enrolled in the phase&nbsp;III study in Cushing&rsquo;s disease. Injection site reactions were also reported in clinical studies in other populations. The reactions were most frequently reported as local pain, erythema, haematoma, haemorrhage and pruritus. These reactions resolved spontaneously and required no intervention.</p><p>&nbsp;</p><p><em>Liver enzymes</em></p><p>Transient elevations in liver enzymes have been reported with the use of somatostatin analogues and were also observed in patients receiving pasireotide in clinical studies. The elevations were mostly asymptomatic, of low grade and reversible with continued treatment. Rare cases of concurrent elevations in ALT greater than 3&nbsp;x&nbsp;ULN and bilirubin greater than 2&nbsp;x&nbsp;ULN have been observed. All cases of concurrent elevations were identified within ten days of initiation of treatment with Signifor. The patients recovered without clinical sequelae and liver function test results returned to baseline values after discontinuation of treatment.</p><p>&nbsp;</p><p>Monitoring of liver enzymes is recommended before and during treatment with Signifor (see section&nbsp;4.4), as clinically appropriate.</p><p>&nbsp;</p><p><em>Pancreatic enzymes</em></p><p>Asymptomatic elevations in lipase and amylase were observed in patients receiving pasireotide in clinical studies. The elevations were mostly low grade and reversible while continuing treatment. Pancreatitis is a potential adverse reaction associated with the use of somatostatin analogues due to the association between cholelithiasis and acute pancreatitis.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses up to 2.1&nbsp;mg twice a day have been used in healthy volunteers, with the adverse reaction diarrhoea being observed at a high frequency.</p><p>&nbsp;</p><p>In the event of overdose, it is recommended that appropriate supportive treatment be initiated, as dictated by the patient&rsquo;s clinical status, until resolution of the symptoms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatostatin and analogues, ATC code: H01CB05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Pasireotide is a novel cyclohexapeptide, injectable somatostatin analogue. Like the natural peptide hormones somatostatin-14 and somatostatin-28 (also known as somatotropin release inhibiting factor [SRIF]) and other somatostatin analogues, pasireotide exerts its pharmacological activity via binding to somatostatin receptors. Five human somatostatin receptor subtypes are known: hsst1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Somatostatin analogues bind to hsst receptors with different potencies (see Table&nbsp;2). Pasireotide binds with high affinity to four of the five hssts.</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Binding affinities of somatostatin (SRIF-14), pasireotide, octreotide and lanreotide to the five human somatostatin receptor subtypes (hsst1‑5)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Compound</strong></p></td><td style="vertical-align:top"><p><strong>hsst1</strong></p></td><td style="vertical-align:top"><p><strong>hsst2</strong></p></td><td style="vertical-align:top"><p><strong>hsst3</strong></p></td><td style="vertical-align:top"><p><strong>hsst4</strong></p></td><td style="vertical-align:top"><p><strong>hsst5</strong></p></td></tr><tr><td style="vertical-align:top"><p>Somatostatin (SRIF-14)</p></td><td style="vertical-align:top"><p>0.93&plusmn;0.12</p></td><td style="vertical-align:top"><p>0.15&plusmn;0.02</p></td><td style="vertical-align:top"><p>0.56&plusmn;0.17</p></td><td style="vertical-align:top"><p>1.5&plusmn;0.4</p></td><td style="vertical-align:top"><p>0.29&plusmn;0.04</p></td></tr><tr><td style="vertical-align:top"><p>Pasireotide</p></td><td style="vertical-align:top"><p>9.3&plusmn;0.1</p></td><td style="vertical-align:top"><p>1.0&plusmn;0.1</p></td><td style="vertical-align:top"><p>1.5&plusmn;0.3</p></td><td style="vertical-align:top"><p>&gt;1,000</p></td><td style="vertical-align:top"><p>0.16&plusmn;0.01</p></td></tr><tr><td style="vertical-align:top"><p>Octreotide</p></td><td style="vertical-align:top"><p>280&plusmn;80</p></td><td style="vertical-align:top"><p>0.38&plusmn;0.08</p></td><td style="vertical-align:top"><p>7.1&plusmn;1.4</p></td><td style="vertical-align:top"><p>&gt;1,000</p></td><td style="vertical-align:top"><p>6.3&plusmn;1.0</p></td></tr><tr><td style="vertical-align:top"><p>Lanreotide</p></td><td style="vertical-align:top"><p>180&plusmn;20</p></td><td style="vertical-align:top"><p>0.54&plusmn;0.08</p></td><td style="vertical-align:top"><p>14&plusmn;9</p></td><td style="vertical-align:top"><p>230&plusmn;40</p></td><td style="vertical-align:top"><p>17&plusmn;5</p></td></tr></tbody></table><p>Results are the mean&plusmn;SEM of IC<sub>50</sub> values expressed as nmol/l.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Somatostatin receptors are expressed in many tissues, especially in neuroendocrine tumours in which hormones are excessively secreted, including ACTH in Cushing&rsquo;s disease.</p><p>&nbsp;</p><p><em>In vitro</em> studies have shown that corticotroph tumour cells from Cushing&rsquo;s disease patients display a high expression of hsst5, whereas the other receptor subtypes either are not expressed or are expressed at lower levels. Pasireotide binds and activates four of the five hssts, especially hsst5, in corticotrophs of ACTH‑producing adenomas, resulting in inhibition of ACTH secretion.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>A phase&nbsp;III, multicentre, randomised study was conducted to evaluate the safety and efficacy of different dose levels of Signifor over a twelve‑month treatment period in Cushing&rsquo;s disease patients with persistent or recurrent disease or <em>de novo</em> patients for whom surgery was not indicated or who refused surgery.</p><p>&nbsp;</p><p>The study enrolled 162&nbsp;patients with a baseline UFC &gt;1.5&nbsp;x&nbsp;ULN who were randomised in a 1:1&nbsp;ratio to receive a subcutaneous dose of either 0.6&nbsp;mg or 0.9&nbsp;mg Signifor twice daily. After three months of treatment, patients with a mean 24-hour UFC &le;2&nbsp;x&nbsp;ULN and below or equal to their baseline value continued blinded treatment at the randomised dose until month&nbsp;6. Patients who did not meet these criteria were unblinded and the dose was increased by 0.3&nbsp;mg twice daily. After the initial 6&nbsp;months in the study, patients entered an additional 6-month open‑label treatment period. If response was not achieved at month&nbsp;6 or if the response was not maintained during the open‑label treatment period, dosage could be increased by 0.3&nbsp;mg twice daily. The dose could be reduced by decrements of 0.3&nbsp;mg twice daily at any time during the study for reasons of intolerability.</p><p>&nbsp;</p><p>The primary efficacy end‑point was the proportion of patients in each arm who achieved normalisation of mean 24-hour UFC levels (UFC &le;ULN) after 6&nbsp;months of treatment and who did not have a dose increase (relative to randomised dose) during this period. Secondary end‑points included, among others, changes from baseline in: 24-hour UFC, plasma ACTH, serum cortisol levels, and clinical signs and symptoms of Cushing&rsquo;s disease. All analyses were conducted based on the randomised dose groups.</p><p>&nbsp;</p><p>Baseline demographics were well balanced between the two randomised dose groups and consistent with the epidemiology of the disease. The mean age of patients was approximately 40&nbsp;years and the majority of patients (77.8%) were female. Most patients (83.3%) had persistent or recurrent Cushing&rsquo;s disease and few (&le;5%) in either treatment group had received previous pituitary irradiation.</p><p>&nbsp;</p><p>Baseline characteristics were balanced between the two randomised dose groups, except for marked differences in the mean value of baseline 24-hour UFC (1156&nbsp;nmol/24&nbsp;h for the 0.6&nbsp;mg twice daily group and 782&nbsp;nmol/24&nbsp;h for the 0.9&nbsp;mg twice daily group; normal range 30‑145&nbsp;nmol/24&nbsp;h).</p><p>&nbsp;</p><p><em>Results</em></p><p>At month&nbsp;6, normalisation of mean UFC levels was observed in 14.6% (95% CI 7.0‑22.3) and 26.3% (95% CI 16.6‑35.9) of patients randomised to pasireotide 0.6&nbsp;mg and 0.9&nbsp;mg twice daily, respectively. The study met the primary efficacy objective for the 0.9&nbsp;mg twice‑daily group as the lower limit of the 95% CI is greater than the pre‑specified 15% boundary. The response in the 0.9&nbsp;mg dose arm seemed to be higher for patients with lower mean UFC at baseline. The responder rate at month&nbsp;12 was comparable to month&nbsp;6, with 13.4% and 25.0% in the 0.6&nbsp;mg and 0.9&nbsp;mg twice‑daily groups, respectively.</p><p>&nbsp;</p><p>A supportive efficacy analysis was conducted in which patients were further classified into 3&nbsp;response categories regardless of up‑titration at month&nbsp;3: Fully controlled (UFC &le;1.0&nbsp;x&nbsp;ULN), partially controlled (UFC &gt;1.0&nbsp;x&nbsp;ULN but with a reduction in UFC &ge;50% compared to baseline) or uncontrolled (reduction in UFC &lt;50%). The total proportion of patients with either full or partial mean UFC control at month&nbsp;6 was 34% and 41% of the randomised patients to the 0.6&nbsp;mg and 0.9&nbsp;mg dose, respectively. Patients uncontrolled at both month&nbsp;1 and month&nbsp;2 are likely (90%) to remain uncontrolled at months&nbsp;6 and 12.</p><p>&nbsp;</p><p>In both dose groups, Signifor resulted in a decrease in mean UFC after 1&nbsp;month of treatment which was maintained over time.</p><p>&nbsp;</p><p>Decreases were also demonstrated by the overall percentage of change in mean and median UFC levels at month&nbsp;6 and 12 as compared to baseline values (see Table&nbsp;3). Reductions in plasma ACTH levels were also observed at each time point for each dose group.</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Percentage change in mean and median UFC levels per randomised dose group at month&nbsp;6 and month&nbsp;12 compared to baseline values</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pasireotide 0.6&nbsp;mg twice daily</p><p>% change (n)</p></td><td style="vertical-align:top"><p>Pasireotide 0.9&nbsp;mg twice daily</p><p>% change (n)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Mean change in UFC (% from baseline)</p></td><td style="vertical-align:top"><p>Month&nbsp;6</p></td><td style="vertical-align:top"><p>‑27.5* (52)</p></td><td style="vertical-align:top"><p>‑48.4 (51)</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>‑41.3 (37)</p></td><td style="vertical-align:top"><p>‑54.5 (35)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Median change in UFC (% from baseline)</p></td><td style="vertical-align:top"><p>Month&nbsp;6</p></td><td style="vertical-align:top"><p>‑47.9 (52)</p></td><td style="vertical-align:top"><p>‑47.9 (51)</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>‑67.6 (37)</p></td><td style="vertical-align:top"><p>‑62.4 (35)</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes one patient with significant outlying results who had a percent change from baseline of +542.2%.</p><p>&nbsp;</p><p>Decreases in sitting systolic and diastolic blood pressure, body mass index (BMI) and total cholesterol were observed in both dose groups at month&nbsp;6. Overall reductions in these parameters were observed in patients with full and partial mean UFC control but tended to be greater in patients with normalised UFC. Similar trends were observed at month&nbsp;12.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Signifor in all subsets of the paediatric population in pituitary‑dependant Cushing&rsquo;s disease, overproduction of pituitary ACTH and pituitary dependant hyperadrenocorticism (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>In healthy volunteers, pasireotide is rapidly absorbed and peak plasma concentration is reached within 0.25‑0.5&nbsp;h. C<sub>max</sub> and AUC are approximately dose‑proportional following administration of single and multiple doses.</p><p>&nbsp;</p><p>No studies have been conducted to evaluate the bioavailability of pasireotide in humans.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>In healthy volunteers, pasireotide is widely distributed with large apparent volume of distribution (V<sub>z</sub>/F &gt;100&nbsp;litres). Distribution between blood cells and plasma is concentration independent and shows that pasireotide is primarily located in the plasma (91%). Plasma protein binding is moderate (88%) and independent of concentration.</p><p>&nbsp;</p><p>Based on <em>in vitro</em> data pasireotide appears to be a substrate of efflux transporter P‑gp (P‑glycoprotein). Based on <em>in vitro</em> data pasireotide is not a substrate of the efflux transporter BCRP (breast cancer resistance protein) nor of the influx transporters OCT1 (organic cation transporter&nbsp;1), OATP (organic anion‑transporting polypeptide) 1B1, 1B3 or 2B1. At therapeutic dose levels pasireotide is also not an inhibitor of UGT1A1, OATP, 1B1 or 1B3, P‑gp, BCRP, MRP2 and BSEP.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Pasireotide is metabolically highly stable and <em>in vitro<strong> </strong></em>data show that pasireotide is not a substrate, inhibitor or inducer of any major enzymes of CYP450. In healthy volunteers, pasireotide is predominantly found in unchanged form in plasma, urine and faeces.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Pasireotide is eliminated mainly via hepatic clearance (biliary excretion), with a small contribution of the renal route. In a human ADME study 55.9&plusmn;6.63% of the radioactive dose was recovered over the first 10&nbsp;days after administration, including 48.3&plusmn;8.16% of the radioactivity in faeces and 7.63&plusmn;2.03% in urine.</p><p>&nbsp;</p><p>Pasireotide demonstrates low clearance (CL/F ~7.6&nbsp;litres/h for healthy volunteers and ~3.8&nbsp;litres/h for Cushing&rsquo;s disease patients). Based on the accumulation ratios of AUC, the calculated effective half‑life (t<sub>1/2,eff</sub>) in healthy volunteers was approximately 12&nbsp;hours.</p><p>&nbsp;</p><p><u>Linearity and time dependency</u></p><p>&nbsp;</p><p>In Cushing&rsquo;s disease patients, pasireotide demonstrates linear and time‑independent pharmacokinetics in the dose range of 0.3&nbsp;mg to 1.2&nbsp;mg twice a day. Population pharmacokinetic analysis suggests that based on C<sub>max</sub> and AUC, 90% of steady state in Cushing&rsquo;s disease patients is reached after approximately 1.5 and 15&nbsp;days, respectively.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>No studies have been performed in paediatric patients.</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>Renal clearance has a minor contribution to the elimination of pasireotide in humans. In a clinical study with single subcutaneous dose administration of 900&nbsp;&micro;g pasireotide in subjects with impaired renal function, renal impairment of mild, moderate or severe degree, or end stage renal disease (ESRD) did not have a significant impact on total pasireotide plasma exposure. The unbound plasma pasireotide exposure (AUC<sub>inf,u</sub>) was increased in subjects with renal impairment (mild: 33%; moderate: 25%, severe: 99%, ESRD: 143%) compared to control subjects.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment</em></p><p>In a clinical study in subjects with impaired hepatic function (Child‑Pugh&nbsp;A, B and C), statistically significant differences were found in subjects with moderate and severe hepatic impairment (Child‑Pugh&nbsp;B and C). In subjects with moderate and severe hepatic impairment, AUC<sub>inf</sub> was increased 60% and 79%, C<sub>max</sub> was increased 67% and 69%, and CL/F was decreased 37% and 44%, respectively.</p><p>&nbsp;</p><p><em>Elderly patients (&ge;65&nbsp;years)</em></p><p>Age has been found to be a covariate in the population pharmacokinetic analysis of Cushing&rsquo;s disease patients. Decreased total body clearance and increased pharmacokinetic exposures have been seen with increasing age. In the studied age range 18‑73&nbsp;years, the area under the curve at steady state for one dosing interval of 12&nbsp;hours (AUC<sub>ss</sub>) is predicted to range from 86% to 111% of that of the typical patient of 41&nbsp;years. This variation is moderate and considered of minor significance considering the wide age range in which the effect was observed.</p><p>&nbsp;</p><p>Data on Cushing&rsquo;s disease patients older than 65&nbsp;years are limited but do not suggest any clinically significant differences in safety and efficacy in relation to younger patients.</p><p>&nbsp;</p><p><em>Demographics</em></p><p>Population pharmacokinetic analyses of Signifor suggest that race and gender do not influence pharmacokinetic parameters.</p><p>&nbsp;</p><p>Body weight has been found to be a covariate in the population pharmacokinetic analysis of Cushing&rsquo;s disease patients. For a range of 60‑100&nbsp;kg the reduction in AUC<sub>ss</sub> with increasing weight is predicted to be approximately 27%, which is considered moderate and of minor clinical significance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical safety data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Most findings seen in repeated toxicity studies were reversible and attributable to the pharmacology of pasireotide. Effects in non‑clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p>&nbsp;</p><p>Pasireotide was not genotoxic in <em>in vitro</em> and <em>in vivo</em> assays.</p><p>&nbsp;</p><p>Carcinogenicity studies conducted in rats and transgenic mice did not identify any carcinogenic potential.</p><p>&nbsp;</p><p>Pasireotide did not affect fertility in male rats but, as expected from the pharmacology of pasireotide, females presented abnormal cycles or acyclicity, and decreased numbers of corpora lutea and implantation sites. Embryo toxicity was seen in rats and rabbits at doses that caused maternal toxicity but no teratogenic potential was detected. In the pre- and postnatal study in rats, pasireotide had no effects on labour and delivery, but caused slight retardation in the development of pinna detachment and reduced body weight of the offspring.</p><p>&nbsp;</p><p>Available toxicological data in animals have shown excretion of pasireotide in milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Mannitol</p><p>Tartaric acid</p><p>Sodium hydroxide</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25⁰C.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One‑point‑cut colourless, type I glass ampoule containing 1&nbsp;ml of solution.</p><p>&nbsp;</p><p>Each ampoule is packed in a cardboard tray which is placed in an outer box.</p><p>&nbsp;</p><p>Multipacks containing 60&nbsp;(10&nbsp;x&nbsp;6)&nbsp;ampoules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signifor solution for injection should be free of visible particles, clear and colourless. Do not use Signifor if the solution is not clear or contains particles.</p><p>&nbsp;</p><p>For information on the instructions for use, please see the end of the package leaflet &ldquo;How to inject Signifor&rdquo;.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG.
www.Novartis.com  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                feb 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>